FDA 483 - The Compounding PHY of Beverly Hills - August 16, 2019

An FDA inspection of The Compounding PHY of Beverly Hills revealed critical deficiencies in their non-sterile drug production. The firm used non-pharmaceutical grade water without quality control, lacked essential laboratory testing for components and finished products, and failed to provide employees with current good manufacturing practices (GMP) training. These findings indicate a severe absence of quality assurance in their compounding operations.